http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105050614-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-544 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-775 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105050614-B |
| titleOfInvention | Peptides with reduced toxicity that stimulate cholesterol efflux |
| abstract | The present invention provides a family of non-naturally occurring polypeptides with similar cholesterol efflux activity to full-length apolipoproteins (eg, Apo AI and Apo E) and similar high selectivity for ABCA1 to full-length apolipoproteins. Furthermore, the peptides of the present invention have little or no toxicity when administered at therapeutic doses and higher. The present invention also provides compositions comprising the polypeptides, methods of identifying, screening and synthesizing the polypeptides, and treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia or inflammation; or involving abnormal glucose metabolism diseases such as diabetes, metabolic syndrome; or Alzheimer's disease or frontotemporal dementia. |
| priorityDate | 2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 903.